Key terms

About PRTA

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest PRTA news

Mar 13 6:20am ET Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA) Mar 07 7:36am ET Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA) Mar 04 4:07pm ET Prothena names David Ford chief people officer Feb 22 5:31pm ET Prothena files to sell ordinary shares, no amount given Feb 21 4:28pm ET Prothena Appoints Daniel G. Welch as New Board Chair Feb 21 4:26pm ET Prothena names Daniel Welch as Director and Chair Designate Feb 20 7:47am ET Prothena price target lowered to $80 from $98 at Oppenheimer Feb 18 11:45pm ET Buy Rating Affirmed on Prothena Amid Strong Pipeline Progress and Solid Financials Feb 16 7:40am ET RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA) Feb 16 7:37am ET Piper Sandler Releases a Buy Rating on Prothena (PRTA) Feb 16 6:25am ET Promising Outlook for Prothena’s Amyloidosis Treatments: Analyst Endorses Buy Rating Feb 16 6:20am ET Prothena price target raised to $85 from $81 at JMP Securities Feb 16 1:41am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 15 4:10pm ET Prothena reports Q4 EPS ($1.26), consensus ($1.22) Jan 30 6:44am ET Prothena downgraded to Neutral from Buy at BofA Jan 25 9:30am ET Prothena price target lowered to $36 from $43 at RBC Capital Jan 25 7:28am ET RBC Capital Remains a Hold on Prothena (PRTA) Jan 17 12:15pm ET Prothena put volume heavy and directionally bearish Jan 11 1:38am ET Buy Rating on Prothena’s Stock Amid Early Positive Signals for Alzheimer’s Drug PRX012 Jan 10 7:18am ET Prothena (PRTA) Gets a Buy from Piper Sandler Jan 09 7:20am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Prothena (PRTA), Johnson & Johnson (JNJ) and Zimmer Biomet Holdings (ZBH) Jan 09 6:50am ET Analysts’ Top Healthcare Picks: Accolade (ACCD), Sarepta Therapeutics (SRPT) Jan 08 7:35pm ET Promising Alzheimer’s Drug and Strong Financials Underpin Buy Rating for Prothena Jan 08 10:05am ET Prothena remains on track with partnered programs, provides updates Jan 02 12:13pm ET The biotech stocks to own in 2024, according to Piper Sandler Dec 21 10:52am ET Biotech Alert: Searches spiking for these stocks today Dec 20 10:42am ET Biotech Alert: Searches spiking for these stocks today Dec 17 5:41am ET These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank

No recent news articles are available for PRTA

No recent press releases are available for PRTA

PRTA Financials

1-year income & revenue

Key terms

PRTA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

PRTA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms